Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

NCT00161668

Last updated date
Study Location
Tucson, Arizona, 85404, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Myeloid Leukemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Treated by Mylotarg

- Provide ICF

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Acute Myeloid LeukemiaStudy Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia NCT00037583
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Acute Myeloid LeukemiaStudy Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia NCT00037596
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Acute Myeloid LeukemiaStudy Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care NCT00161668
  1. Tucson, Arizona
  2. Berkely, California
  3. Burbank, California
  4. Concord, California
  5. Loma Linda, California
  6. Los Angeles, California
  7. San Francisco, California
  8. Sylmar, California
  9. Denver, Colorado
  10. Boynton Beach, Florida
  11. Plantation, Florida
  12. Stuart, Florida
  13. Tamarac, Florida
  14. Chicago, Illinois
  15. Chicago, Illinois
  16. Chicago, Illinois
  17. Chicago, Illinois
  18. Indianapolis, Indiana
  19. Iowa City, Iowa
  20. Lexington, Kentucky
  21. Louisville, Kentucky
  22. Shrevport, Louisiana
  23. Ann Arbor, Michigan
  24. Grand Rapids, Michigan
  25. Kalamazoo, Michigan
  26. Kalamazoo, Michigan
  27. Columbia, Missouri
  28. St. Louis, Missouri
  29. Neptune, New Jersey
  30. Albuquerque, New Mexico
  31. Bronx, New York
  32. Buffalo, New York
  33. New Hyde Park, New York
  34. New York, New York
  35. New York, New York
  36. Valhalla, New York
  37. Durham, North Carolina
  38. Winston-Salem, North Carolina
  39. Bismarck, North Dakota
  40. Akron, Ohio
  41. Canton, Ohio
  42. Cincinnati, Ohio
  43. Cleveland, Ohio
  44. Oklahoma City, Oklahoma
  45. Portland, Oregon
  46. Hershey, Pennsylvania
  47. Philadelphia, Pennsylvania
  48. Philadelphia, Pennsylvania
  49. Pittsburgh, Pennsylvania
  50. Memphis, Tennessee
  51. Nashville, Tennessee
  52. Nashville, Tennessee
  53. Houston, Texas
  54. Temple, Texas
  55. Arlington, Virginia
  56. Richmond, Virginia
  57. Charleston, West Virginia
  58. Morgantown, West Virginia
  59. Appleton, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Acute Myeloid LeukemiaA Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT01546038
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. La Jolla, California
  5. La Jolla, California
  6. La Jolla, California
  7. Los Angeles, California
  8. Los Angeles, California
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. Los Angeles, California
  14. Los Angeles, California
  15. San Diego, California
  16. Aurora, Colorado
  17. Aurora, Colorado
  18. Tampa, Florida
  19. Atlanta, Georgia
  20. Atlanta, Georgia
  21. Atlanta, Georgia
  22. Atlanta, Georgia
  23. Chicago, Illinois
  24. Chicago, Illinois
  25. Chicago, Illinois
  26. Chicago, Illinois
  27. Chicago, Illinois
  28. Fairway, Kansas
  29. Kansas City, Kansas
  30. Westwood, Kansas
  31. Baltimore, Maryland
  32. Boston, Massachusetts
  33. Boston, Massachusetts
  34. Boston, Massachusetts
  35. Boston, Massachusetts
  36. Ann Arbor, Michigan
  37. Ann Arbor, Michigan
  38. Creve Coeur, Missouri
  39. Saint Louis, Missouri
  40. Saint Louis, Missouri
  41. Saint Louis, Missouri
  42. Saint Louis, Missouri
  43. Hackensack, New Jersey
  44. Hackensack, New Jersey
  45. Buffalo, New York
  46. Cleveland, Ohio
  47. Nashville, Tennessee
  48. Nashville, Tennessee
  49. Nashville, Tennessee
  50. Houston, Texas
  51. Seattle, Washington
  52. Seattle, Washington
  53. Hamilton, Ontario
  54. Greenfield Park, Quebec
  55. Ulm, Baden-wuerttemberg
  56. Frankfurt am Main, Hessen
  57. Hannover, Lower Saxony
  58. Berlin,
  59. Berlin,
  60. Hamburg,
  61. Kiel,
  62. Magdeburg,
  63. Mainz,
  64. Muenster,
  65. Ulm,
  66. Bologna, Province OF Bologna
  67. Milano,
  68. Rome,
  69. Torino,
  70. Udine,
  71. Gdansk, Pomorskie
  72. Lodz,
  73. Wroclaw,
  74. Sevilla, Andalucia
  75. Badalona, Barcelona
  76. Barcelona,
  77. Barcelona,
  78. Barcelona,
  79. Barcelona,
  80. Madrid,
  81. Valencia,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Official Title Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Brief Summary This study is designed to assess the safety of Mylotarg therapy in routine practice.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Not Provided
Study Population Not Provided
Condition Acute Myeloid Leukemia
Intervention Drug: Mylotarg
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Enrollment
 (submitted: September 11, 2005)
500
Original Enrollment Same as current
Study Completion Date Not Provided
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

  • Treated by Mylotarg
  • Provide ICF
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT00161668
Other Study ID Numbers 0903X-100847
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date March 2007